News
The FDA has removed the recommended pause in the use of Valneva’s chikungunya vaccine Ixchiq in individuals aged 60 years and older.
15h
MedPage Today on MSNSoap Recall Over Sepsis Risk; FDA Rehires Vinay Prasad; NIH Reports Patient to ICENote that some links may require registration or subscription. DermaRite Industries is recalling certain lots of its over-the ...
The uncertainty surrounds who will be able to get updated vaccines in coming months – shots created to protect against more ...
Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...
In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related hospitalization and 76-96% against COVID-associated death. Despite the shift away ...
This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...
Overall, the initial steps of the wind-down will result the in the cancellation of nearly $500 million. Not all mRNA related ...
Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results